Navigation Links
QLT announces first quarter results for 2008
Date:4/25/2008

to: our projections of 2008 sales of Visudyne and our share of profit from Visudyne sales; our projection of 2008 sales of Eligard; our projections of R&D expense and SG&A expense for 2008; our plans to divest certain core and non-core assets described in the press release; our future business plans and strategy focusing on our Visudyne franchise and the clinical programs relating to Visudyne, our punctal plug drug delivery technology and our photodynamic therapy dermatology technology; and statements which contain language such as: "assuming," "prospects," "future," "projects," "believes," "expects" and "outlook." Forward-looking statements are predictions only which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those expressed in such statements. Many such risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: the Company's future operating results are uncertain and likely to fluctuate; currency fluctuations in primary markets might impact financial results; the risk that future sales of Visudyne and Eligard may be less than expected (including as a result of the timing and impact of existing competitive products and/or new products launched by competitors, reimbursement levels, and the level of physician acceptance of Visudyne in combination with other agents); the Company's reliance on third parties for the manufacture and marketing of Visudyne and Eligard; our ability to successfully complete the sale of one or more of the assets or operations at an acceptable price and the time period necessary to complete such sales are uncertain; fluctuations in the real estate market; uncertainties relating to the timing and results of the clinical development and commercialization of our products and technologies (including Visudyne, our punctal plug technology and our photo
'/>"/>
SOURCE QLT Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
4. HEI, Inc. Announces Sale of RFID Division Assets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
8. Brooke Franchise Corporation Announces Selected July Results
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... ... August 04, 2015 , ... School is almost back in session. Parents and ... for the back-to-school scramble. Dublin, OH family dentist , Dr. Cheung (of BrightSmile ... annual dental checkup. In fact, the dentist recently updated the practice’s surgical suite to ...
(Date:8/4/2015)... ... ... Many men are confused about the safety of testosterone replacement therapy. In ... voice of authority for men seeking accurate information about testosterone. , Renew Man™ ... in the safe and effective treatment of low testosterone. In recent years, the experts ...
(Date:8/4/2015)... ... August 04, 2015 , ... Buckeye Health Plan is reminding ... immunizations are covered for members under the Healthchek program . , “Many ... with their immunizations may not be allowed to attend when school begins in ...
(Date:8/4/2015)... ... August 04, 2015 , ... SanusEO, ... Bruce McCalley joins its executive leadership team as Senior Vice President of Sales ... technology companies and expanding global markets with a special emphasis on the healthcare ...
(Date:8/4/2015)... ... August 04, 2015 , ... T.E.N., an information technology ... participating in The ISE® Lions’ Den and Jungle Lounge 2015, which will be held ... Vegas. , During the event, eight emerging security vendors, known as “Gazelles,” will go ...
Breaking Medicine News(10 mins):Health News:Dublin OH Family Dentist Offers Complimentary Back-to-School Cleanings, a Revamped Suite, and In-House Esthetician to Accommodate All Patients 2Health News:Dublin OH Family Dentist Offers Complimentary Back-to-School Cleanings, a Revamped Suite, and In-House Esthetician to Accommodate All Patients 3Health News:Dublin OH Family Dentist Offers Complimentary Back-to-School Cleanings, a Revamped Suite, and In-House Esthetician to Accommodate All Patients 4Health News:New Video from Renew Man™ Raises Awareness of the Right Way to Correct Low Testosterone 2Health News:New Video from Renew Man™ Raises Awareness of the Right Way to Correct Low Testosterone 3Health News:Buckeye Health Plan Reminds Parents to Keep Immunizations In Mind As School Year Kicks Off 2Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 2Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 3Health News:T.E.N. Releases Pitch Schedule for The ISE® Lions Den & Jungle Lounge 2015 2Health News:T.E.N. Releases Pitch Schedule for The ISE® Lions Den & Jungle Lounge 2015 3Health News:T.E.N. Releases Pitch Schedule for The ISE® Lions Den & Jungle Lounge 2015 4
... release is available in Spanish . U.S. ... laboratory rats fed blueberries or other foods of interest may ... has paved the way to follow-up experiments, Rosalia C. M. ... Rock, Ark., has determined that several indicators of rat mammary ...
... more common disease striking overweight, younger women is the ... where an osteopathic physician is testing the effectiveness of ... Idiopathic intracranial hypertension, known as IIH or pseudo-tumor cerebri, ... the brain, specifically in the absence of a tumor. ...
... year, 10,000 pregnant women and up to 200,000 newborn babies ... globe have for years been looking in vain for a ... have found the biochemically weakness of the lethal malaria parasite, ... related malaria. The malaria parasite travels via the spit ...
... with colon cancer that had spread to distant sites found ... drug regimen that was not recommended. Those patients were exposed ... for the drugsof more than $2 million. The study, ... the American Society for Clinical Oncology,s annual meeting in Chicago, ...
... Blocking two tiny molecules of RNA a chemical ... of blood vessels that occurs in degenerative eye disorders, UT ... in the Proceedings of the National Academy of Sciences ... (AMD), a vascular eye disorder that affects nearly 2 million ...
... (HealthDay News) -- One of the first and largest national ... that those who identify as gay, lesbian or bisexual are ... The study was conducted by the U.S. Centers for ... 2001-2009. It found that rates of smoking, drinking or other ...
Cached Medicine News:Health News:Mammary gland development of blueberry-fed lab animals studied 2Health News:Researcher tests drug's impact on neurological disease affecting women 2Health News:Researchers discover biochemical weakness of malaria parasite -- vaccine to be developed 2Health News:Many patients with advanced cancers get treatments that won't help 2Health News:Many patients with advanced cancers get treatments that won't help 3Health News:Researchers find that inhibiting microRNAs may help prevent degenerative eye disorders 2Health News:More Risky Behaviors Among Gay, Bisexual High School Students: CDC 2
(Date:8/4/2015)...  Sutro Biopharma today announced that it has ... president of alliance and project management. Dr. Vasquez ... of Sutro,s collaborative partnerships and the development of ... antibodies and antibody-based therapeutics targeting immuno-oncology pathways. ... of experience in the biopharmaceutical sector with expertise ...
(Date:8/4/2015)... -- Delcath Systems, Inc. (NASDAQ: DCTH ), a specialty ... an emphasis on the treatment of primary and metastatic ... studies in Europe and the ... Delivery System (CHEMOSAT) will be presented at the upcoming ... be held in Marseille, France , ...
(Date:8/4/2015)... , Aug. 4, 2015 BioElectronics ... over-the-counter ActiPatch® Musculoskeletal Pain Therapy medical devices, announced ... of its ActiPatch 7-day trial device has been ... Pain Management http://www.futuremedicine.com/doi/full/10.2217/PMT.15.35 .  More ... survey and submitted an assessment.  ...
Breaking Medicine Technology:Sutro Biopharma Appoints Nicki Vasquez, Ph.D. as VP of Alliance and Project Management 2Delcath Announces Acceptance of Abstracts for Presentation at the European Association of Dermato Oncology Annual Congress 2Delcath Announces Acceptance of Abstracts for Presentation at the European Association of Dermato Oncology Annual Congress 3Delcath Announces Acceptance of Abstracts for Presentation at the European Association of Dermato Oncology Annual Congress 4BioElectronics' Landmark 5,000+ Chronic Pain Patient Study Published in Pain Management Medical Journal 2
... DIEGO, Oct. 7 The West Wireless Health ... to Alan Viars, of Videntity, at the Health ... and open source platforms to enable people to ... networks as they work towards achieving health and ...
... 7 VentiRx Pharmaceuticals, Inc., a biopharmaceutical company ... 8 (TLR8) candidates for the treatment of cancer, ... its randomized, placebo controlled clinical trial evaluating VTX-1463 ... demonstrated that VTX-1463 significantly improved allergy symptoms based ...
Cached Medicine Technology:West Wireless Health Institute Awards $10K Developer Challenge at Health 2.0 2West Wireless Health Institute Awards $10K Developer Challenge at Health 2.0 3VentiRx Pharmaceuticals Reports Positive Clinical Data for VTX-1463 in Allergic Rhinitis 2
... the only dura material versatile enough for ... closure, and in cases where biological fixation ... in cases requiring an immediate watertight seal ... biological fixation and sealing are key factors ...
The Bovie IDS Series are the latest electrosurgical generators with fully digital implementation....
Aaron 1250 is a multipurpose electrosurgical generator with monopolar and bi-polar functions....
Bipolar foot activated forceps....
Medicine Products: